Journal article
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
Shankar Siva, Mathias Bressel, Mark Sidhom, Swetha Sridharan, Ben GL Vanneste, Ryan Davey, Rebecca Montgomery, Jeremy Ruben, Farshad Foroudi, Braden Higgs, Charles Lin, Avi Raman, Nicholas Hardcastle, Michael S Hofman, Richard De Abreu Lourenco, Mark Shaw, Pascal Mancuso, Daniel Moon, Lih-Ming Wong, Nathan Lawrentschuk Show all
The Lancet Oncology | Elsevier | Published : 2024
Abstract
Background: Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surgical resection. The FASTRACK II clinical trial investigated the efficacy of SABR for primary renal cell cancer in a phase 2 trial. Methods: This international, non-randomised, phase 2 study was conducted in seven centres in Australia and one centre in the Netherlands. Eligible patients aged 18 years or older had biopsy-confirmed diagnosis of primary renal cell cancer, with only a single lesion; were medically inoperable, were at high risk of complications from surgery, or declined surgery; and had an Eastern Cooperative Oncology Gro..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
Funding Cancer Australia Priority -driven Collaborative Cancer Research Scheme.